Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23160932 | 0.84 | HTT (0.47) | PKMPOLBHTTKDM4EMAPT | |
| SCHEMBL9878843 | 0.81 | ADORA1 (0.44) | PKMPOLBHTTKDM4EMAPT | |
| SCHEMBL798506 | 0.79 | PKM (0.58) | PKMPOLBHTTKDM4EMAPT | |
| SCHEMBL9878574 | 0.76 | POLB (0.61) | POLBHTTKDM4ESMN1; SMN2HPGD | |
| SCHEMBL29232331 | 0.76 | SMN1; SMN2 (0.52) | HTTKDM4EMAPTSMN1; SMN2HPGD | |
| SCHEMBL9697629 | 0.73 | MAPT (0.60) | PKMPOLBHTTKDM4EMAPT | |
| SCHEMBL5124123 | 0.72 | PKM (0.41) | PKMPOLBHTTKDM4EMAPT | |
| SCHEMBL117000 | 0.72 | PKM (0.41) | PKMPOLBHTTKDM4EMAPT | |
| SCHEMBL17594977 | 0.72 | PKM (0.41) | PKMPOLBHTTKDM4EMAPT | |
| SCHEMBL10852387 | 0.71 | HCAR2 (0.37) | PKMHTTKDM4ESMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759082-B1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | PROCOS SPA (IT) | 2022-04-20 | — | — | EP | claimed |
| US-11028057-B2 | Process for the synthesis of 6-chloromethyluracil | PROCOS S.P.A. (IT) | 2021-06-08 | — | — | US | claimed |
| EP-3759082-A1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | Procos S.p.A. (IT) | 2021-01-06 | — | — | EP | claimed |
| US-20200407330-A1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | PROCOS S.P.A. (IT) | 2020-12-31 | — | — | US | claimed |
| EP-3759082-B1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | PROCOS SPA (IT) | 2022-04-20 | — | — | EP | disclosed |
| EP-3759082-B1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | PROCOS SPA (IT) | 2022-04-20 | — | — | EP | disclosed |
| US-11028057-B2 | Process for the synthesis of 6-chloromethyluracil | PROCOS S.P.A. (IT) | 2021-06-08 | — | — | US | disclosed |
| US-11028057-B2 | Process for the synthesis of 6-chloromethyluracil | PROCOS S.P.A. (IT) | 2021-06-08 | — | — | US | disclosed |
| EP-3759082-A1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | Procos S.p.A. (IT) | 2021-01-06 | — | — | EP | disclosed |
| US-20200407330-A1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | PROCOS S.P.A. (IT) | 2020-12-31 | — | — | US | disclosed |
| US-20200407330-A1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | PROCOS S.P.A. (IT) | 2020-12-31 | — | — | US | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
| US-4604466-A | INTERMEDIATES FOR BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4478835-A | BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1984-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | PKM 538/4885POLB 397/4885HTT 4389/4885 |
| US-11028057-B2 | Process for the synthesis of 6-chloromethyluracil | DHPS, TPMT, MPST | PKM 1409/4885POLB 209/4885HTT 1906/4885 |
| US-20200407330-A1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | DHPS, TPMT, MPST | PKM 1409/4885POLB 209/4885HTT 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.